A Window of Opportunity Study of Patritumab Deruxtecan in Patients With Brain Metastases
Status:
Not yet recruiting
Trial end date:
2027-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if the study drug, patritumab deruxtecan
(HER3-DXd), can be measured in brain tumor tissue after recieving one dose of patritumab
deruxtecan before surgery.